PET scan study for early active systemic sclerosis
Part of Skin clinical trials.
This trial uses PET/CT scans with special tracers to look at inflammation and activity in systemic sclerosis (scleroderma) soon after symptoms begin. It may help researchers understand what’s driving active disease and where it shows up in the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re an adult with active systemic sclerosis (SSc).
- Your first non–Raynaud symptom started within the last 5 years.
- Your disease is considered active, based on nailfold blood vessel changes and/or higher inflammation blood tests (CRP or ESR).
- You have no other autoimmune disease or inflammatory joint disease besides systemic sclerosis.
- You have not used most immune-suppressing medicines or biologic medicines before starting the study (some limits apply).
- You have not had recent steroid shots by mouth/injection or certain blood-vessel medications within 4 weeks before the scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a new drug called telitacicept can safely help people with systemic sclerosis (scleroderma) who still have active disease despite standard treatments. It aims to see if the drug can slow or improve skin thickening and other symptoms.
This trial tests a new cell injection treatment (RY_SW01) for people with systemic sclerosis (a condition causing skin thickening and organ issues). It aims to see if the therapy can improve skin hardening and overall symptoms.
This early study uses a PET scan (a type of imaging test) to better understand lung blood-vessel disease in people who have pulmonary hypertension related to scleroderma. It may help researchers find how imaging signals relate to disease and risk.
This study uses a special PET scan called PSMA to look at inflammation in Sjögren's syndrome, comparing the results with another type of PET scan (FAPI). It may help doctors better understand the disease and find new ways to track it.
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
This trial uses a special PET/CT scan with a tracer called 68Ga-FAPI-46 to see if it can better detect inflammation and scarring (fibrosis) in people with chronic diseases like scleroderma, pulmonary fibrosis, or rheumatoid arthritis. The goal is to improve diagnosis and monitoring.
Hear when a new Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.